首頁 > 市場調查報告書 > 醫療設備

病患監測

市場調查報告書

商品編碼

1559455

肺活量計 - 市場考察、競爭格局、市場預測 (2030)

Spirometers - Market Insights, Competitive Landscape, and Market Forecast - 2030

出版日期: 2024年09月01日 | 出版商:

DelveInsight | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

到2030年，全球肺活量計市場規模預計將達到 18.0166億美元，2024-2030年預測期間年複合成長率為 4.65%。由於幾個關鍵因素，預計市場將顯著成長。首先，包括慢性阻塞性肺病 (COPD) 和氣喘在內的呼吸系統疾病負擔的增加強調了對有效診斷和監測工具的需求，增加了對肺活量計的需求。吸煙人數的迅速增加進一步加劇了呼吸道疾病，並增加了定期進行肺功能檢查以控制和預防疾病進展的需求。此外，人們對呼吸系統健康意識的提高和廣泛篩檢計畫的實施促進早期檢測和干預，並促進採用肺活量測定法作為標準診斷工具。此外，隨著主要市場參與者不斷創新和推出具有改進功能和技術的先進肺活量測定設備，市場隨著產品發布和批准的增加而增強。預計這些因素將共同促進2024-2030年預測期內肺活量計市場的擴張。

肺活量計市場動態

根據Australian Institute of Health and Welfare提供的最新資料，預計2022年澳洲約有850萬人 (34%) 患有慢性呼吸道疾病。

此外，根據Global Burden of Disease (2023年) 的最新資料，全球約有每20 人中就有 1 人患有慢性呼吸道疾病。

此外，根據世界衛生組織 (WHO) 提供的最新資料 (2023年) ，吸菸是慢性阻塞性肺病的主要原因，慢性阻塞性肺病是一種常見的肺部疾病，會導致呼吸困難，並已奪走了許多人的生命。約 3.92億人患有慢性阻塞性肺病，其中約 75%生活在低收入和中等收入國家。在高收入國家，吸菸佔 COPD 病例的70%以上。

由於吸菸和環境因素導致呼吸系統疾病的盛行率增加，對肺活量計的需求不斷成長，這對於將藥物直接輸送到肺部以有效緩解症狀和進行疾病管理非常重要。

此外，根據 GLOBOCAN 最新提供的資料，預計2022年全球將新增氣管癌、支氣管癌和肺癌病例 248萬例，到2045年將新增 425萬例。慢性阻塞性肺病是一種主要由吸菸引起的進行性呼吸道疾病，需要定期評估肺功能來控制症狀並追蹤疾病進展。隨著慢性阻塞性肺病發病率的增加，醫療保健提供者越來越依賴肺活量計來評估肺活量和氣流阻塞，這使得這些設備對於診斷和持續管理非常重要。同樣，吸菸率的迅速增加導致包括慢性阻塞性肺病在內的呼吸系統疾病的發生率增加，增加了對肺活量測定的需求。吸菸者和前吸菸者通常是定期肺功能篩檢的候選人，以發現早期損傷跡象並防止進一步惡化。

此外，該公司策略性地擴大其市場佔有率，並透過擴大肺活量計生產和獲得監管部門的批准來推動進一步成長。例如，2024年 1月，NuvoAir Medical 宣布其創新的Air Next 肺活量計獲得正式 510 (k) 許可，可作為完整的肺活量計在家庭中使用。此次批准使 NuvoAir 能夠擴大其臨床業務，並確保不遺漏任何患有心臟病或肺病的患者。

此外，肺活量測定法臨床試驗的成功為市場帶來了巨大動力，增加了成長前景並鼓勵增加興趣和投資。例如，2023年1月，開發實證數位生物標記的醫療科技公司Koneksa宣布啟動臨床試驗。本研究比較了家用移動肺活量測定法和使用數位生物標記的診所肺量測定法對接受長效 β 受體促效劑 (LABA) 治療的中度氣喘患者的治療效果。

因此，上述因素可能會在預測期內推動肺活量計市場的發展。

然而，峰值流量計、二氧化碳計、影像技術和脈搏血氧計等替代設備的出現可能會阻礙未來肺活量計市場的發展。

本報告研究和分析了全球肺活量計市場，提供了每個地區的市場規模和預測、過去三年的產品/技術發展以及每個細分市場的業績和前景等資訊。

FUKUDA SANGYO CO., LTD.
Midmark Corporation
CHEST M.I., Inc.
KoKo PFT
Clarity Medical Pvt. Ltd.
COSMED srl
Jones Medical Instrument Company
Baxter
Teleflex Incorporated
VYAIRE MEDICAL, INC.
SIBEL, S.A.U.
Medikro Oy
ICU Medical Inc.
Vitalograph
Futuremed USA
Schiller AG
Aksia Group SGR S.p.A
CONTEC MEDICAL SYSTEMS CO., LTD.
NDD Medical Technologies
MGC DIAGNOSTICS CORPORATION

第9章 KOL觀點

第10章專案方法

第11章關於 DelveInsight

第12章免責聲明，聯絡我們

簡介目錄圖表

Product Code: DIMDCL0092

Spirometers by Type (Table Top and Portable), Technology (Volume Measurement and Flow Measurement), Application (Asthma, Chronic Obstructive Pulmonary Disease [COPD], Cystic Fibrosis, and Others), End-User (Hospitals, Clinics, and Home Care), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2030 owing to the rising burden of respiratory diseases, the surge in cigarette smoking, increasing awareness and screening programs, and increase in product launches and approvals by key market players across the globe.

The spirometer market will grow at a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 1,801.66 million by 2030. The market for spirometer is set to experience significant growth driven by several key factors. Firstly, the rising burden of respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, underscores the need for effective diagnostic and monitoring tools, thereby increasing the demand for spirometer. The surge in cigarette smoking further exacerbates respiratory conditions, heightening the necessity for routine lung function testing to manage and prevent disease progression. Additionally, increasing awareness about respiratory health and the implementation of widespread screening programs are fostering early detection and intervention, which fuels the adoption of spirometry as a standard diagnostic tool. Furthermore, the market is being bolstered by a rise in product launches and approvals from key market players, who are continuously innovating and introducing advanced spirometry devices with improved features and technology. These factors are expected to collectively contribute to the expanding market for spirometer during the forecast period from 2024 to 2030.

Spirometers Market Dynamics:

According to the latest data provided by the Australian Institute of Health and Welfare, in 2022, around 8.5 million (34%) people in Australia were estimated to have chronic respiratory conditions.

Additionally, as per the recent data provided by the Global Burden of Disease (2023), approximately, 1 in 20 people globally suffers from chronic respiratory diseases.

Furthermore, as per the recent data provided by the World Health Organization (2023), smoking was a major cause of chronic obstructive pulmonary disease, a common lung condition that led to breathing difficulties and claimed over 3 million lives annually. Approximately 392 million people have COPD, with about 75% living in low- and middle-income countries. In high-income countries, tobacco smoking was responsible for over 70% of COPD cases.

As the incidence of respiratory disorders rises, driven largely by smoking and environmental factors, there is a heightened need for Spirometers, which are critical in delivering medication directly to the lungs for effective symptom relief and disease management.

Additionally, as per the recent data provided by GLOBOCAN, in 2022, globally the estimated new cases of trachea, bronchus, and lung cancer was 2.48 million, and the projections are expected to rise by 4.25 million by the year 2045. COPD, a progressive respiratory condition primarily caused by smoking, requires regular assessment of lung function to manage symptoms and track disease progression. As COPD prevalence rises, healthcare providers are increasingly relying on spirometer to evaluate lung capacity and airflow obstruction, making these devices essential for both diagnosis and ongoing management. Similarly, the surge in smoking rates contributes to a higher incidence of respiratory disorders, including COPD, which in turn drives the need for spirometry tests. Smokers and former smokers are often targeted for regular lung function screening to detect early signs of damage and prevent further deterioration.

Additionally, companies are amplifying their production of spirometer and securing regulatory approvals, thereby strategically expanding their market presence and driving further growth. For instance, in January 2024, NuvoAir Medical announced that its innovative Air Next Spirometer had received formal 510(k) clearance for in-home use as a full spirometer. This approval allowed NuvoAir to scale and expand its clinical operations, ensuring that no patient with heart or lung conditions was left behind.

Moreover, the success of the clinical trial on spirometry gave a significant boost to the market, enhancing its growth prospects and driving increased interest and investment. For instance, in January 2023, Koneksa, a healthcare technology company that developed evidence-based digital biomarkers, announced the launch of a clinical study. The study compared the treatment effects of at-home mobile spirometry using digital biomarkers with in-clinic spirometry in patients with moderate asthma who were on long-acting beta-agonist (LABA) treatment.

Thus, the factors mentioned above are likely to boost the market of spirometers during the forecasted period.

However, the availability of alternative devices such as peak flow meters, capnometers, imagining techniques, and pulse oximeters may hinder the future market of spirometers.

Spirometers Market Segment Analysis:

In the type segment of the spirometer market, the portable spirometer is expected to hold a significant share in 2023. Portable spirometers are significantly boosting the overall spirometer market by enhancing accessibility and convenience for both patients and healthcare providers. These compact, handheld devices allow for real-time monitoring of lung function outside of traditional clinical settings, enabling patients to conduct tests at home or on the go. This increased accessibility is particularly valuable for managing chronic respiratory conditions like asthma and COPD, where regular monitoring is crucial. Portable spirometers also facilitate early detection and intervention, as patients can perform frequent tests without needing to visit a healthcare facility. Additionally, advancements in connectivity and integration with mobile health apps have enabled seamless data sharing with healthcare providers, improving remote patient management and personalized care. The growing adoption of portable spirometers reflects a shift towards more proactive and patient-centered healthcare, driving market growth as these devices become an integral part of routine respiratory health management.

In addition, new product launches are also likely to upsurge the global spirometer market during the forecasted period. For instance, in November 2021, Cipla announced the launch of Spirofy(R), India's first pneumotach-based portable, wireless spirometer, on World COPD Day. With this launch, the company aimed to revolutionize the diagnosis of Obstructive Airway Disease (OAD) and strengthen its position as a leader in lung health in India. This was part of the Company's LungAttack campaign, which sought to raise awareness about COPD and promote early diagnosis. Additionally, a shift in trend from table-top to portable devices will offer assistance in remote settings. This will increase the acceptance of spirometers for patients.

Hence, all the above-mentioned factors are expected to generate considerable revenue for the segment pushing the overall growth of the global spirometer market during the forecast period.

North America is expected to dominate the overall spirometer market:

North America is expected to account for the highest proportion of the spirometer market in 2023, out of all regions. This can be ascribed to the increasing prevalence of respiratory disease across the region, the increase in technological advancement, the surge in cigarette smoking, the increase in government initiatives coupled with increased awareness programs for respiratory disorders, and the presence of key market players engaged in merger, acquisition, product launches, and other market activities across the region are expected to escalate the market of Spirometers during the forecast period.

According to the recent data and stats provided by the American Lung Association (2024), in 2022, among children, asthma was more common in males accounting for 7.0% of the population in the United States and 5.4% in females. Additionally, as per the same source, asthma among adults is 10.8% for females and 6.5% for females across the region of the United States. Asthma management requires regular monitoring of lung function to adjust treatment plans and prevent exacerbations. Spirometers allow patients to track their lung function over time, providing critical data to healthcare providers for optimizing treatment strategies. This continuous need for monitoring drives the market for both in-clinic and portable spirometers.

Additionally, as per the data provided by the Centre for Disease Control and Prevention (2024), in 2022, 4.6% of adults had been diagnosed with COPD, emphysema, or chronic bronchitis in the United States.

Furthermore, as per the recent data and stats provided by the Centre for Disease Control and Prevention (2023), in 2021, approximately 11.5% of U.S. adults aged 18 and older smoked cigarettes, totaling around 28.3 million smokers. At that time, over 16 million Americans were living with a smoking-related disease. The spirometer market is significantly boosted by the increasing prevalence of chronic respiratory conditions such as COPD, emphysema, and chronic bronchitis, alongside rising smoking rates. These conditions, which are often exacerbated by smoking, require regular and accurate monitoring of lung function for effective management and treatment. Spirometers are essential tools for diagnosing and tracking these diseases, as they measure vital lung parameters such as airflow and lung volume.

The increasing number of product development activities in the region is further going to accelerate the growth of the spirometer market. For instance, in August 2021, Roundworks Technologies Private Limited announced the approval of 510(k) for its Alveoair Digital Spirometer. Alveoair(R) is a personal spirometer designed for asthma, COPD, cystic fibrosis, and ILD patients to help quantify their lung health.

Furthermore, in March 2023, Clario, a healthcare research technology company known for its endpoint technology solutions for clinical trials, announced a partnership with the technology startup ArtiQ. This collaboration aimed to improve the accuracy of respiratory clinical trials that require spirometry data. The partnership allowed for AI-based reviews of spirometry data collected on the Clario platform.

Therefore, the above-mentioned factors are expected to bolster the growth of the spirometer market in North America during the forecast period.

Spirometers Market Key Players:

Some of the key market players operating in the Spirometers market include FUKUDA SANGYO CO., LTD., Midmark Corporation, CHEST M.I., Inc., KoKo PFT, Clarity Medical Pvt. Ltd., COSMED srl, Jones Medical Instrument Company, Baxter, Teleflex Incorporated, VYAIRE MEDICAL, INC., SIBEL, S.A.U., Medikro Oy, ICU Medical Inc., Vitalograph, Futuremed USA, Schiller AG, Aksia Group SGR S.p.A, CONTEC MEDICAL SYSTEMS CO., LTD, NDD Medical Technologies, MGC DIAGNOSTICS CORPORATION, and others.

Recent Developmental Activities in the Spirometers Market:

In September 2022, RxCap, Inc., a cloud-based remote monitoring company, and ZEPHYRx LLC, a provider of remote respiratory monitoring solutions, announced their partnership to integrate ZEPHYRx's cloud spirometry platform with RxCap's remote monitoring platform.
In March 2022, KoKo, LLC, a software developer and medical device manufacturer, and MAGNET group, a purchasing organizations (GPO) company signed a three-year partnership contract that allows access to all of KoKo's "gold standard" lung function diagnostics and software for spirometry, diffusion capacity, and PFT.

Key Takeaways From the Spirometers Market Report Study:

Market size analysis for current spirometer size (2023), and market forecast for 6 years (2024 to 2030)
Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years
Key companies dominating the spirometer market.
Various opportunities available for the other competitors in the spirometer market space.
What are the top-performing segments in 2023? How these segments will perform in 2030?
Which are the top-performing regions and countries in the current spirometer market scenario?
Which are the regions and countries where companies should have concentrated on opportunities for spirometer market growth in the coming future?

Target Audience who can be Benefited From This Spirometers Market Report Study:

Spirometers product providers
Research organizations and consulting companies
Spirometers -related organizations, associations, forums, and other alliances
Government and corporate offices
Start-up companies, venture capitalists, and private equity firms
Distributors and traders dealing in spirometer
Various end-users who want to know more about the spirometer market and the latest technological developments in the spirometer market.

Frequently Asked Questions for the Spirometers Market:

1. What are spirometers?

The spirometer is a medical device that is used for performing spirometry tests to examine the function of the lungs. It is a very valuable tool for studying multiple respiratory problems such as asthma, chronic obstructive pulmonary disease (COPD), and others. It is also used to evaluate possible occupational pulmonary disorders and can be used to test lung functioning before surgery.

2. What is the market for spirometers?

The spirometer market will grow at a CAGR of 4.65% during the forecast period from 2024 to 2030 to reach USD 1,801.66 million by 2030.

3. What are the drivers for the spirometer market?

The spirometer market is set to experience significant growth driven by several key factors. Firstly, the rising burden of respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, underscores the need for effective diagnostic and monitoring tools, thereby increasing the demand for spirometers. The surge in cigarette smoking further exacerbates respiratory conditions, heightening the necessity for routine lung function testing to manage and prevent disease progression. Additionally, increasing awareness about respiratory health and the implementation of widespread screening programs are fostering early detection and intervention, which fuels the adoption of spirometry as a standard diagnostic tool. Furthermore, the market is being bolstered by a rise in product launches and approvals from key market players, who are continuously innovating and introducing advanced spirometry devices with improved features and technology. These factors are expected to collectively contribute to the expanding market for spirometers during the forecast period from 2024 to 2030.

4. Who are the key players operating in the spirometer market?

5. Which region has the highest share in the spirometer market?

1. Spirometers Market Report Introduction

1.1. Scope of the Study
1.2. Market Segmentation
1.3. Market Assumption

2. Spirometers Market Executive Summary

2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

4.1. The United States
4.2. Europe
4.3. Japan
4.4. China

5. Spirometers Market Key Factors Analysis

5.1. Spirometers Market Drivers
- 5.1.1. The rising burden of chronic respiratory diseases
- 5.1.2. The surge in cigarette smoking
- 5.1.3. Increasing awareness and screening programs
- 5.1.4. Increase in product launches and approvals by key market players across the globe.
5.2. Spirometers Market Restraints and Challenges
- 5.2.1. The availability of alternative devices such as peak flow meters, capnometers, imagining techniques, and pulse oximeters
5.3. Spirometers Market Opportunities
- 5.3.1. The increase in the shift towards home-based healthcare solutions
- 5.3.2. Integration of digital health and artificial intelligence

6. Spirometers Market Porter's Five Forces Analysis

6.1. Bargaining Power of Suppliers
6.2. Bargaining Power of Consumers
6.3. Threat of New Entrants
6.4. Threat of Substitutes
6.5. Competitive Rivalry

7. Spirometers Market Assessment

7.1. By Type
- 7.1.1. Table Top
- 7.1.2. Portable
7.2. By Portability
- 7.2.1. Volume Measurement
- 7.2.2. Flow Measurement
7.3. By Application
- 7.3.1. Asthma
- 7.3.2. Chronic Obstructive Pulmonary Disease (COPD)
- 7.3.3. Cystic Fibrosis
- 7.3.4. Others
7.4. By End-User
- 7.4.1. Hospitals
- 7.4.2. Clinics
- 7.4.3. Homecare
7.5. By Geography
- 7.5.1. North America
  - 7.5.1.1. United States Spirometers Market Size in USD Million (2021-2030)
  - 7.5.1.2. Canada Spirometers Market Size in USD Million (2021-2030)
  - 7.5.1.3. Mexico Spirometers Market Size in USD Million (2021-2030)
- 7.5.2. Europe
  - 7.5.2.1. France Spirometers Market Size in USD Million (2021-2030)
  - 7.5.2.2. Germany Spirometers Market Size in USD Million (2021-2030)
  - 7.5.2.3. United Kingdom Spirometers Market Size in USD Million (2021-2030)
  - 7.5.2.4. Italy Spirometers Market Size in USD Million (2021-2030)
  - 7.5.2.5. Spain Spirometers Market Size in USD Million (2021-2030)
  - 7.5.2.6. Rest of Europe Spirometers Market Size in USD Million (2021-2030)
- 7.5.3. Asia-Pacific
  - 7.5.3.1. China Spirometers Market Size in USD Million (2021-2030)
  - 7.5.3.2. Japan Spirometers Market Size in USD Million (2021-2030)
  - 7.5.3.3. India Spirometers Market Size in USD Million (2021-2030)
  - 7.5.3.4. Australia Spirometers Market Size in USD Million (2021-2030)
  - 7.5.3.5. South Korea Spirometers Market Size in USD Million (2021-2030)
  - 7.5.3.6. Rest of Asia-Pacific Spirometers Market Size in USD Million (2021-2030)
- 7.5.4. Rest of the World (RoW)
  - 7.5.4.1. Middle East Spirometers Market Size in USD Million (2021-2030)
  - 7.5.4.2. Africa Spirometers Market Size in USD Million (2021-2030)
  - 7.5.4.3. South America Spirometers Market Size in USD Million (2021-2030)

8. Spirometers Market Company and Product Profiles

8.1. FUKUDA SANGYO CO., LTD.
- 8.1.1. Company Overview
- 8.1.2. Company Snapshot
- 8.1.3. Financial Overview
- 8.1.4. Product Listing
- 8.1.5. Entropy
8.2. Midmark Corporation
- 8.2.1. Company Overview
- 8.2.2. Company Snapshot
- 8.2.3. Financial Overview
- 8.2.4. Product Listing
- 8.2.5. Entropy
8.3. CHEST M.I., Inc.
- 8.3.1. Company Overview
- 8.3.2. Company Snapshot
- 8.3.3. Financial Overview
- 8.3.4. Product Listing
- 8.3.5. Entropy
8.4. KoKo PFT
- 8.4.1. Company Overview
- 8.4.2. Company Snapshot
- 8.4.3. Financial Overview
- 8.4.4. Product Listing
- 8.4.5. Entropy
8.5. Clarity Medical Pvt. Ltd.
- 8.5.1. Company Overview
- 8.5.2. Company Snapshot
- 8.5.3. Financial Overview
- 8.5.4. Product Listing
- 8.5.5. Entropy
8.6. COSMED srl
- 8.6.1. Company Overview
- 8.6.2. Company Snapshot
- 8.6.3. Financial Overview
- 8.6.4. Product Listing
- 8.6.5. Entropy
8.7. Jones Medical Instrument Company
- 8.7.1. Company Overview
- 8.7.2. Company Snapshot
- 8.7.3. Financial Overview
- 8.7.4. Product Listing
- 8.7.5. Entropy
8.8. Baxter
- 8.8.1. Company Overview
- 8.8.2. Company Snapshot
- 8.8.3. Financial Overview
- 8.8.4. Product Listing
- 8.8.5. Entropy
8.9. Teleflex Incorporated
- 8.9.1. Company Overview
- 8.9.2. Company Snapshot
- 8.9.3. Financial Overview
- 8.9.4. Product Listing
- 8.9.5. Entropy
8.10. VYAIRE MEDICAL, INC.
- 8.10.1. Company Overview
- 8.10.2. Company Snapshot
- 8.10.3. Financial Overview
- 8.10.4. Product Listing
- 8.10.5. Entropy
8.11. SIBEL, S.A.U.
- 8.11.1. Company Overview
- 8.11.2. Company Snapshot
- 8.11.3. Financial Overview
- 8.11.4. Product Listing
- 8.11.5. Entropy
8.12. Medikro Oy
- 8.12.1. Company Overview
- 8.12.2. Company Snapshot
- 8.12.3. Financial Overview
- 8.12.4. Product Listing
- 8.12.5. Entropy
8.13. ICU Medical Inc.
- 8.13.1. Company Overview
- 8.13.2. Company Snapshot
- 8.13.3. Financial Overview
- 8.13.4. Product Listing
- 8.13.5. Entropy
8.14. Vitalograph
- 8.14.1. Company Overview
- 8.14.2. Company Snapshot
- 8.14.3. Financial Overview
- 8.14.4. Product Listing
- 8.14.5. Entropy
8.15. Futuremed USA
- 8.15.1. Company Overview
- 8.15.2. Company Snapshot
- 8.15.3. Financial Overview
- 8.15.4. Product Listing
- 8.15.5. Entropy
8.16. Schiller AG
- 8.16.1. Company Overview
- 8.16.2. Company Snapshot
- 8.16.3. Financial Overview
- 8.16.4. Product Listing
- 8.16.5. Entropy
8.17. Aksia Group SGR S.p.A
- 8.17.1. Company Overview
- 8.17.2. Company Snapshot
- 8.17.3. Financial Overview
- 8.17.4. Product Listing
- 8.17.5. Entropy
8.18. CONTEC MEDICAL SYSTEMS CO., LTD.
- 8.18.1. Company Overview
- 8.18.2. Company Snapshot
- 8.18.3. Financial Overview
- 8.18.4. Product Listing
- 8.18.5. Entropy
8.19. NDD Medical Technologies
- 8.19.1. Company Overview
- 8.19.2. Company Snapshot
- 8.19.3. Financial Overview
- 8.19.4. Product Listing
- 8.19.5. Entropy
8.20. MGC DIAGNOSTICS CORPORATION
- 8.20.1. Company Overview
- 8.20.2. Company Snapshot
- 8.20.3. Financial Overview
- 8.20.4. Product Listing
- 8.20.5. Entropy